Plato Investment Management Ltd Grows Position in Boston Scientific Corporation $BSX

Plato Investment Management Ltd boosted its stake in Boston Scientific Corporation (NYSE:BSX) by 49.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 42,706 shares of the medical equipment provider’s stock after acquiring an additional 14,144 shares during the period. Plato Investment Management Ltd’s holdings in Boston Scientific were worth $4,092,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in BSX. Parnassus Investments LLC boosted its holdings in Boston Scientific by 42,978.9% in the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock valued at $672,128,000 after acquiring an additional 6,868,459 shares in the last quarter. Egerton Capital UK LLP raised its stake in Boston Scientific by 223.7% in the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after buying an additional 3,671,548 shares in the last quarter. Jennison Associates LLC raised its stake in Boston Scientific by 133.5% in the third quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock worth $482,170,000 after buying an additional 2,823,744 shares in the last quarter. Alphinity Investment Management Pty Ltd bought a new position in Boston Scientific in the fourth quarter worth about $252,918,000. Finally, Marshall Wace LLP raised its stake in Boston Scientific by 30.7% in the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock worth $956,680,000 after buying an additional 2,301,383 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $53.89 on Friday. The company has a current ratio of 1.90, a quick ratio of 1.08 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $80.08 billion, a P/E ratio of 22.55, a P/E/G ratio of 0.99 and a beta of 0.62. The business has a fifty day simple moving average of $65.95 and a two-hundred day simple moving average of $83.68. Boston Scientific Corporation has a 12 month low of $53.63 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. TD Cowen decreased their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Weiss Ratings downgraded shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, February 4th. Robert W. Baird decreased their price target on shares of Boston Scientific from $86.00 to $78.00 and set an “outperform” rating for the company in a research note on Thursday, April 23rd. Evercore decreased their price target on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Finally, Canaccord Genuity Group lowered their price objective on Boston Scientific from $109.00 to $71.00 and set a “buy” rating for the company in a research report on Thursday, April 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $93.91.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.